# Eight Roads Ventures

> Eight Roads Ventures is a VC fund in London backing Software and Health Care. See 385 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 385
- Last investment: Aug 2026
- Lead investor: 41%
- Fund size: $350M
- Last fund: Mar 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eight-roads/?originalSubdomain=in
- X (Twitter): https://twitter.com/8roadsventures
- Website: https://eightroads.com/en/

Eight Roads Ventures is a global venture capital firm managing $11bn of assets across offices in the UK, China, India, Japan, and the US. Together with our associated funds, including our US sister fund F-Prime Capital, our 50-year history of investing includes partnerships with over 500 companies such as Alibaba, AppsFlyer, Chewy, Fareye, Fever,Flywire, Fireblocks, Funnel.io, Gloat, Hibob, Icertis, Neo4j, Otrium, Owkin, Paidy, Spendesk, Tibber, Toast, Wallapop and Xoom.

## Contacts

5 contacts available for Eight Roads Ventures. Shizune tracks 23 team members at Eight Roads Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eight-roads-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.5M–$62M |
| Series B | $8.5M–$85M |
| Series C | $15M–$118M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 54 | 14% |
| Health Care | 53 | 14% |
| Information Technology | 45 | 12% |
| Biotechnology | 43 | 11% |
| Medical | 31 | 8% |

238 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 114 | 30% |
| Series A | 89 | 23% |
| Series C | 59 | 15% |
| Funding Round | 28 | 7% |
| Series D | 22 | 6% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 81 | 21% |
| China | 52 | 14% |
| India | 31 | 8% |
| Japan | 24 | 6% |
| United Kingdom | 24 | 6% |

20 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aditya Systla | Partner | 12 | https://shizune.co/investors/profile/aditya-gurunath-systla |
| Gordon Zhang | Vice President & Principal | 1 | https://shizune.co/investors/profile/gordon-zhang |
| Jarlon Tsang | Managing Partner, Head of China | 1 | https://shizune.co/investors/profile/jarlon-tsang |
| Michael Treskow | Partner | 13 | https://shizune.co/investors/profile/michael-treskow |
| Prem Pavoor | Partner | 8 | https://shizune.co/investors/profile/prem-pavoor |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BlissClub | BlissClub is the community's first women's activewear brand. | $16.8M | Venture - Series Unknown | Aug 07, 2026 |  |
| Sonosemi Medical | Sonosemi Medical is a provider of medical devices that specializes in the development of pan-vascular active interventional products, diagnosis, and treatment solutions. |  | Series B | Jul 08, 2026 |  |
| Exponent Energy | Exponent Energy focuses on developing fast charging technology for electric vehicles.Exponent Energy's energy stack can speed up and simplify energy and charging for their client's electric vehicles which ensures the least amount of impedance buildup and results in a continuous flow of energy.The company also offers customers abattery management system, battery pack, and charger that all function in concert.Exponent Energy was established in 2020 by Arun Vinayak and Sanjay Byalal Jagannath in Bangalore, Karnataka. | $21M | Series B | Jun 10, 2026 |  |
| Immuneel Therapeutics | Immuneel Therapeutics Pvt Ltd is a pioneering startup company leading the charge in cell therapy and personalized immunotherapy for patients | $10.5M | Series B | Jun 08, 2026 |  |
| Tenpoint Therapeutics | Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | $85M | Series B | Jan 28, 2026 |  |
| AssetPlus | AssetPlus focuses on offering digital-first solutions to financial advisors and mutual fund distributors. | $19.3M | Series B | Jan 19, 2026 |  |
| Wint Wealth | GrowFix offers high net-worth individuals and retail investors, asset-backed fixed income products that offer higher returns than fixed deposits. | $27.7M | Series B | Jan 14, 2026 |  |
| Amenitiz | We created Amenitiz because we believe technology is the key to making success and profitability accessible to every hotelier in the world - whether they are in the heart of Paris or in the Uyuni Salt Flats in Bolivia. Our mission is to build an all-in-one platform to help owners grow and manage their vacation properties by making attractingguests, managing bookings and crafting exceptional experiences, simple and easy. We invite you to be part of our growing community and help us redefine the future of online hospitality together. | $45M | Series B | Nov 11, 2025 |  |
| ABK Biomedical | ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization. | $35M | Series D | Oct 14, 2025 |  |
| Safe Security | Safe Security offers a unified platform that quantifies and manages enterprise‑wide cyber risk in real time. It provides modules for Cyber Risk Quantification (CRQ), Third‑Party Risk Management (TPRM), Continuous Threat Exposure Management (CTEM), and support for cyber insurance processes. The platform aggregates automated signals across people,processes, technology, external threats, and vendors, and uses agent‑based AI to generate risk scores, projected financial impact, and prioritized actions. The solution delivers continuous monitoring, benchmarking, and risk reporting that aligns cybersecurity metrics with business objectives | $70M | Series C | Jul 31, 2025 |  |

10 of 385 investments shown.

## Co-investors
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 112 deals together
- [Elevation Capital](https://shizune.co/investors/profile/elevation-capital-6e8a) — VC Fund, 13 deals together
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund, 11 deals together
- [Arbor Ventures](https://shizune.co/investors/profile/arbor-ventures) — VC Fund, 11 deals together
- [Index Ventures](https://shizune.co/investors/profile/index-ventures) — VC Fund, 10 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Practica Capital](https://shizune.co/investors/profile/practica-capital) — VC Fund
- [Coinvest Capital](https://shizune.co/investors/profile/coinvest-capital) — VC Fund
- [Iron Wolf Capital](https://shizune.co/investors/profile/iron-wolf-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Asia](https://shizune.co/investors/biotechnology-investors-asia)
- [Biotechnology VC Funds in Asia](https://shizune.co/investors/biotechnology-vc-funds-asia)
- [Biotech Investors in Asia](https://shizune.co/investors/biotech-investors-asia)
- [Biotech VC Funds in Asia](https://shizune.co/investors/biotech-vc-funds-asia)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)

## FAQ

### What does Eight Roads Ventures invest in?

Eight Roads Ventures invests primarily in Software, Health Care and Information Technology startups, most often at Series B and Series A stage. Most of the 385 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Eight Roads Ventures's check size?

Eight Roads Ventures typically joins rounds of $6.5M–$62M at Series A, $8.5M–$85M at Series B and $15M–$118M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eight Roads Ventures participates in.

### How do I contact Eight Roads Ventures?

Public channels for Eight Roads Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eight Roads Ventures?

The team at Eight Roads Ventures includes Aditya Systla (Partner), Gordon Zhang (Vice President & Principal) and Jarlon Tsang (Managing Partner, Head of China), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co